Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing M(r) 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)

Clinical Cancer Research

Volumn 4, Issue 7, 1998, Pages 1661-1672

  Beran, Miloslav ^a,c   Cao, Xiaobo ^a   Estrov, Zeev ^a   Jeha, Sima ^a   Jin, Guozhong ^a   O'Brien, Susan ^a   Talpaz, Moshe ^a   Arlinghaus, Ralph B ^a   Lydon, Nicholas B ^b   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CIBA GEIGY LTD   (Switzerland)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 22; CYTOTOXICITY; DOSE RESPONSE; ENZYME ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; PHILADELPHIA CHROMOSOME; PHOSPHORYLATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TUMOR CELLS, CULTURED;

EID: 15444350807     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rowley, J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.), 243-290, 1973.
2. Kurzrock, R., Gutterman, J. U., and Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med., 319: 990-998, 1988.
3. Davis, R. L., Konopka, J. B., and Witte, O. N. Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered abl proteins with similar in vitro kinase properties. Mol. Cell. Biol., 5: 204-213, 1985.
4. Kloetzer, W., Kurzrock, R., Smith, L., Talpaz, M., Spiller, M., Gutterman, J., and Arlinghaus, R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 leukemia cells unmasks associated tyrosine kinase activity. Virology, 740: 230-238, 1985.
5. Knopka, J. B., Watanabe, S. M., and Witte, O. N. Alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine activity. Cell, 37: 1035-1042, 1984.
6. Daley, G. Q., Van Etten, R. A., and Baltimore, D. Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science (Washington DC), 247: 824-830, 1990.
7. Heisterkamp, N., Jenster, G., Ten Hoeve, J., Zovich, D., Pattengale, P. K., and Groffen, J. Acute leukemia in bcr/abl transgenic mice. Nature, 344: 251-253, 1990.
8. Westbrook, C. A., Hooberman, A. L., Spino, C., Dodge, R. K., Larson, R. A., Davey, F., Wurster-Hill, D. H., Sobol, R. E., Schiffer, C., and Bloomfield, C. D. Clinical significance of the bcr-abl fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood, 80: 2983-2990, 1992.
9. Preti, H. A., O'Brien, S., Giralt, S., Beran, M., Pierce, S., and Kantarjian, H. Philadelphia chromosome-positive adult lymphoblastic leukemia-characteristics, treatment, results, and prognosis. Am. J. Med., 97: 256-261, 1994.
10. 1-positive acute lymphocytic leukemia (ALL). Science (Washington DC), 239: 775-777, 1988.
11. Acute myeloid leukemia. In: F. Mittelman (ed.), Catalog of Chromosome Aberrations in Cancer, Ed. 5, p. 3470. New York: Wiley-Liss Publishers, 1994.
12. Melo, J. V. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 88: 2375-2384, 1996.
13. Pane, F., Frigeri, F., Sindona, M., Luciano, L., Ferrara, F., Cimino, R., Meloni, G., Saglio, G., Salvatore, F., and Rotoli, B. Neutrophilic-chronic myelogenous leukemia: a distinct disease with a specific molecular marker (BCR-ABL with c3a2 junction). Blood, 88: 2410-2414, 1996.
14. Buchdunger, E., Zimmerman, T., Mett, H., Meger, T., Miller, M., Regenass, U., and Lydon, M. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a novel tyrosine protein kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA., 92: 2558-2562, 1995.
15. Buchdunger, E., Zimmermann, T., Mett, H., Meyer, T., Muller, M., Drucker, B. J., and Lydon, N. B. Inhibition of the abl protein-kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 56: 100-104, 1996.
16. Furet, P., Caravatti, G., Lydon, N., Priestle, J. P., Sowadski, J. M., Trinks, U., and Traxler, P. Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput. Aided Mol. Des., 9: 465, 1995.
17. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmerman, J., and Lydon, N. B. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of Bcr-Abl-positive cells. Nat. Med., 2: 561-566, 1996.
18. Lanenville, P., Heisterkamp, N., and Groffen, J. Expression of the chronic myelogenous leukemia-associated p210 bcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene, 6: 275-282, 1991.
19. Andersson, B. S., Bergerheim, U. S. R., Collins, V. P., Childs, C., and Beran, M. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp. Hematol., 20: 361-367, 1992.
20. Beran, M., Pisa, P., O'Brien, S., Kurzrock, R., Siciliano, M., Cork, A., Andersson, B. S., Kohli, V., and Kantarjian, H. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from a chronic myelogenous leukemia cells in the blastic phase. Cancer Res., 53: 1-9, 1993.
21. Wetzler, M., Talpaz, M., Van Etten, R. A., Hirsch-Ginsberg, C., Beran, M., and Kurzrock, R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J. Clin. Invest., 92: 1925-1939, 1993.
22. Andersson, B. S., Beran, M., Pathak, S., Goodacre, A., Barlogie, B., and McCredie, K. B. Ph-positive chronic myeloid with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet. Cytogenet., 24: 335-343, 1987.
23. 1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181). J. Cell Physiol., 166: 618-630, 1996.
24. Estrov, Z., Talpaz, M., Ku, S., Harris, D., LaPushin, R., Koller, C. A., Hirsch-Ginsberg, C., Huh, Y., Yee, G., and Kurzrock, R. Molecular and biologic characterization of a newly established Philadelphia-positive acute lymphoblastic leukemia cell line (Z-33) with autocrine response to GM-CSF. Leukemia (Baltimore), 10: 1534-1543, 1996.
25. Lu, D., Liu, T., Campbell, M., Guo, J. Q., Heisterkamp, N., Groffen, T., Canaani, E., and Arlinghaus, R. B. Tyrosine phosphorylation of p160 bcr by p210 bcr-abl. Blood, 82: 1257-1263, 1993.
26. Liu, T., Wu, T., and Arlinghaus, R. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-abl and the bcr-abl oncoprotein. Cancer Res., 45: 5120-5124, 1996.
27. Mossan, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
28. Schmid, I., Uittenbogaart, C. H., and Giorgi, J. V. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry, 15: 12-20, 1994.
29. Yaish, P., Gazit, A., Gilon, C., and Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (Washington DC), 242: 933-935, 1988.
30. Levitzki, A. Tyrophostines: tyrosine kinase blockers as novel anti-proliferative agents and dissectors of signal transduction. FASEB J., 6: 3275, 1992.
31. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 267: 1782, 1995.
32. bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood, 82: 3524, 1993.
33. bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anti-Cancer Drugs, 5: 213-222, 1994.
34. Cheng, K. D., Kurzrock, R., Estrov, Z., Levitzki, A., Kantarjian, H., Beran, M., Qiu, X. G., McBride, M., Clarkson, B., and Talpaz, M. Leukemia cell line inhibition of cell proliferation, autophosphorylation, kinase activity, and induction of apoptosis by tyrphostin AG1112 and AG957. Blood, 88: 3512, 1996.
35. Deininger, M. W. N., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90: 3691-3696, 1997.
36. Kantarjian, H., O'Brien, S., Beran, M., Keating, M., Koller, C., Robertson, L, Andreeff, M., Murphy, S., and Freireich, E. Update of hyper-cvad program in newly-diagnosed adult acute lymphocytic leukemia (ALL). Blood, 86: 680, 1995.